Krogsgaard: We set the bar higher for ourselves
Novo Nordisk’s science chief, Mads Krogsgaard Thomsen, is pleased with last week’s cardiovascular data for diabetes drug Victoza, but he also admits that it will have consequences for the future of the company’s research efforts, which will now have a changed focus.
BY STEFAN SINGH KAILAY
Novo Nordisk’s Chief Scientific Officer, Mads Krogsgaard Thomsen, says he spends more time on clinical data than he does on the stock market. So he was not too affected when last week’s long-awaited cardiovascular data from the company’s blockbuster drug Victoza were met with disappointment in the market, leading to a slumping share price.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s prize asset shows potential in Alzheimer’s
For abonnenter
